patient
treat
amiodaron
accumul
lysobisphosphatid
acid
lbpa
also
known
bi
monoacylglycero
phosphat
airway
secret
develop
differ
tissu
vacuol
inclus
bodi
thought
origin
endosom
clarifi
origin
chang
studi
vitro
effect
amiodaron
endosom
activ
like
transferrin
recycl
shiga
toxin
process
escrtdepend
lentiviru
bud
fluid
phase
endocytosi
proteolysi
exosom
secret
furthermor
sinc
accumul
lbpa
might
point
broader
disturb
lipid
homeostasi
studi
effect
amiodaron
distribut
lbpa
unesterifi
cholesterol
sphingomyelin
glycosphyngolipid
amiodaron
analogu
also
studi
includ
recent
develop
deriv
dronedaron
found
amiodaron
affect
earli
endosom
activ
like
transferrin
recycl
shiga
toxin
process
lentiviru
bud
amiodaron
instead
interfer
late
compart
endocyt
pathway
block
progress
fluid
phase
endocytosi
caus
fusion
organel
collaps
lumen
structur
accumul
undegrad
substrat
amass
differ
type
lipid
late
endocyt
compart
affect
sinc
exosom
secret
spare
chang
recal
niemannpick
typec
phenotyp
npc
origin
differ
mechan
sinc
differ
npc
allevi
cholesterol
remov
studi
analogu
indic
basic
pka
high
watersolubl
acid
ph
crucial
requir
interfer
late
endosomeslysosom
respect
dronedaron
least
potent
amiodaron
find
may
relev
field
unrel
rhythm
control
elsevi
inc
right
reserv
abbrevi
lbpa
lysobisphosphatid
acid
escrt
endosom
sort
complex
requir
transport
vlp
viru
like
particl
amiodaron
cation
antiarrhythm
drug
extens
use
control
supraventricular
ventricular
arrhythmia
action
mechan
includ
blockad
kand
na
channel
interfer
badrenoreceptor
ca
current
amiodaron
larg
volum
distribut
lkg
steadi
state
serum
level
mm
elimin
halflif
sever
week
propens
accumul
differ
tissu
like
adipos
tissu
skelet
muscl
liver
brain
recent
evid
suggest
accumul
tissu
might
happen
least
two
mechan
associ
cell
membran
due
high
lypophil
amiodaron
trap
lumen
acid
organel
proton
amin
function
present
later
group
diethylaminobethoxi
amiodaron
catabol
includ
stepwis
dealkyl
deamin
later
group
diethylaminoethoxi
major
metabolit
ndesethylamiodaron
mdea
whose
activ
serum
level
similar
parent
drug
chronic
exposur
amiodaron
induc
format
vacuol
inclus
bodi
blood
leukocyt
cell
corneal
epithelium
skin
cell
alveolar
macrophag
liver
cell
cardiomyocyt
although
agreement
structur
deriv
interfer
amiodaron
endocyt
pathway
uncertainti
set
endocyt
organel
involv
mechan
format
vacuol
origin
materi
amorph
membranelik
accumul
lumen
inclus
bodi
regard
section
endocyt
pathway
involv
claim
amiodaron
interfer
earli
compart
endocyt
pathway
sinc
drug
modifi
distribut
earli
endosom
marker
howev
issu
remain
undecid
sinc
found
interfer
amiodaron
activ
diphtheria
toxin
whose
activ
moieti
enter
cytoplasm
earli
endosom
other
found
amiodaron
inhibit
toxin
side
sever
line
evid
suggest
amiodaron
interfer
late
compart
endocyt
pathway
fact
vacuol
inclus
bodi
bear
marker
late
endosomeslysosom
like
ii
patient
treat
amiodaron
accumul
airway
lysobisphosphatid
acid
lbpa
also
known
bi
monoacylglycero
phosphat
compon
late
endosom
lumen
membran
iii
amiodaron
inhibit
vitro
activ
anthrax
toxin
whose
subunit
edema
factor
lethal
factor
enter
cytoplasm
late
endosomesmultivesicular
bodi
thu
far
unknown
whether
amiodaron
interfer
recycl
endosom
pathway
connect
directli
earli
endosom
golgi
known
amiodaron
interfer
escrt
complex
highli
conserv
set
protein
associ
special
portion
earli
endosom
necessari
format
lumen
vesicl
eventu
matur
compart
multivesicular
bodi
escrt
system
also
involv
membran
deform
topolog
equival
endovesicul
like
cytokinesi
bud
membran
bound
virus
interestingli
mutat
escrt
system
lead
phenotyp
character
presenc
vacuol
inclus
bodi
bear
marker
earli
late
endosom
observ
patient
treat
amiodaron
accumul
lbpa
detect
late
endosom
intim
connect
unesterifi
cholesterol
suggest
drug
might
alter
distribut
lipid
found
niemannpick
type
c
diseas
mutat
protein
caus
accumul
free
cholesterol
glycosphyngolipid
sphingosin
lbpa
sphingomyelin
late
endosomeslysosom
interestingli
niemannpick
type
c
cell
accumul
lipid
manifest
disturb
traffic
also
play
pathogenet
role
sinc
allevi
phenotyp
obtain
decreas
cholesterol
level
inhibit
glycosphingolipid
synthesi
increas
lipid
degrad
recent
shown
niemannpick
type
c
cell
tri
combat
cholesterol
accumul
increas
secret
exosom
vesicl
locat
lumen
late
endosomesmultivesicular
bodi
destin
secret
rather
destroy
specul
happen
niemannpick
type
c
diseas
increas
lbpa
level
observ
patient
treat
amiodaron
might
point
complex
disturb
homeostasi
cell
lipid
order
clarifi
issu
examin
effect
amiodaron
differ
endosom
activ
includ
transferrin
recycl
escrt
function
evalu
lentivirus
bud
pathway
connect
earli
endosom
golgi
complex
probe
shiga
toxin
process
within
earli
endosom
move
golgi
vesicular
intermedi
furthermor
analyz
effect
amiodaron
secret
exosom
distribut
lipid
traffick
late
endosomeslysosom
like
lbpa
cholesterol
sphingomyelin
glycosphyngolipid
besid
sinc
vacuol
may
reflect
disord
fluid
phase
endocytosi
studi
effect
amiodaron
traffic
nondegrad
sugar
final
correl
physicochem
properti
amiodaron
analogu
effect
distribut
lbpa
abil
degrad
import
protein
particular
analogu
studi
includ
dronedaron
amiodaron
deriv
recent
introduc
clinic
practic
found
amiodaron
concentr
close
patient
serum
level
interfer
late
compart
endocyt
pathway
block
progress
fluid
phase
endocytosi
caus
inappropri
fusion
organel
collaps
lumen
structur
accumul
undegrad
substrat
amass
lipid
chang
recal
niemannpick
type
c
npc
phenotyp
origin
differ
mechan
sinc
allevi
cholesterol
remov
cell
treat
npcphenotyp
induc
revert
normal
reduct
cholesterol
load
studi
analogu
indic
high
watersolubl
acid
ph
crucial
requir
interfer
late
endosom
lysosom
respect
dronedaron
least
potent
amiodaron
bhk
vero
cell
obtain
european
collect
cell
cultur
ecacc
human
fibroblast
obtain
normal
skin
biopsi
grown
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
uml
penicillin
mgml
streptomycin
sigmaaldrich
saint
loui
mo
cell
obtain
ecacc
grown
rpmi
medium
fetal
calf
serum
mgml
streptomycin
uml
penicillin
sigmaaldrich
rabbit
alveolar
macrophag
obtain
bronchoalveolar
lavag
circul
monocyt
obtain
healthi
blood
donor
cultur
ringer
buffer
mm
nacl
mm
kcl
mm
mgcl
mm
na
hpo
mm
glucos
mm
hepe
ph
plu
bovin
serum
albumin
sigmaaldrich
previous
report
human
embryon
kidney
cell
stabli
transduc
express
simian
viru
antigen
kindli
provid
prof
baltimor
rockefel
univers
new
york
ny
usa
cell
viabil
test
trypan
blue
exclus
assay
base
reduct
tetrazolium
salt
cell
prolifer
kit
mtt
roch
diagnost
mannheim
germani
data
present
cell
viabl
respect
control
cell
sourc
dr
taamotsu
yoshimori
addgen
cambridg
kind
gift
dr
robert
lodg
laval
univers
quebec
citi
canada
addgen
plasmid
contain
gagpol
rev
encod
sequenc
felin
immunodefici
viru
fiv
strain
genbank
access
construct
contain
complet
proviru
molecular
clone
transfect
done
use
attracten
transfect
reagent
qiagen
milan
itali
accord
protocol
provid
supplier
calcium
phosphat
procedur
mous
antibodi
anti
lbpa
echelon
bioscienc
logan
ut
mous
anti
atubulin
sigmaaldrich
rabbit
anti
novu
biolog
littleton
co
rabbit
anti
giantin
anti
abcam
cambridg
uk
mous
anti
development
studi
hybridoma
bank
univers
iowa
ia
secondari
antibodi
conjug
alexa
fluor
fitc
molecular
probe
eugen
santa
cruz
biotechnolog
santa
cruz
ca
amiodaron
sigmaaldrich
dronedaron
extract
multaq
commerci
pill
sanofiaventi
munchenstein
switzerland
briefli
one
multitaq
tablet
dissolv
ml
nh
extract
time
ml
methylen
chlorid
organ
phase
collect
dri
reduc
pressur
dissolv
dmso
store
analogu
use
studi
whose
synthesi
report
previous
present
tabl
shiga
toxin
gener
gift
dr
maurizio
brigotti
depart
experiment
patholog
univers
bologna
itali
surfact
protein
spa
isol
therapeut
lung
lavag
fluid
patient
suffer
alveolar
proteinosi
label
specif
activ
cpmng
protein
previous
report
acid
hpt
tetramethylrhodamin
dextran
kda
mw
molecular
probe
eugen
pxylenebispyridiniumbromid
dpx
chemi
brunschwig
basel
switzerland
tm
biostatu
limit
shepsh
uk
h
leucin
specif
activ
cimmol
amersham
pharmacia
biotech
littl
chalfont
uk
hyonic
fluor
packard
groningen
netherland
benzonas
novagen
san
diego
ca
complet
proteas
inhibitor
cocktail
roch
diagnost
mannheim
germani
creatin
phosphokinas
boehring
mannheim
germani
lysenin
lysenin
antiserum
peptid
institut
osaka
japan
reagent
sigmaaldrich
cell
adher
glass
coverslip
falcon
milan
itali
incub
h
differ
drug
fix
paraformaldehyd
pfa
pb
min
quench
mm
nh
cl
min
permeabil
mg
digitoninml
pb
min
block
gelatin
pb
min
incub
primari
antibodi
h
appropri
secondari
antibodi
min
stain
cell
mount
vectashield
vector
laboratori
burlingam
ca
analyz
leica
tc
laserscan
confoc
microscop
dilut
primari
antibodi
anti
lbpa
anti
anti
giantin
anti
pictur
present
least
duplic
experi
stain
lbpa
cell
counterstain
propidium
iodid
randomli
select
cell
profil
lbpaposit
structur
count
diamet
measur
count
diamet
measur
done
blind
fashion
two
independ
observ
imag
obtain
confoc
resid
softwar
data
present
cell
profil
lbpaposit
structur
treatment
cell
fix
pfa
min
quench
mm
nh
cl
min
incub
h
mg
filipinml
bsa
pb
mount
glycerolpb
analyz
leica
dmr
epifluoresc
microscop
sphingomyelin
stain
use
lysenin
kda
poreform
toxin
eisenia
foetida
bind
sphingomyelin
briefli
cell
adher
glass
coverslip
fix
quench
permeabil
report
section
block
gelatinpb
min
afterward
cell
incub
ice
h
mgml
lysenin
gelatin
pb
rins
extens
pb
room
temperatur
incub
h
antibodi
antilysenin
anti
lbpa
gelatinpb
expos
appropri
secondari
antibodi
min
mount
analyz
confoc
microscopi
traffick
glycosphingolipid
analyz
use
borondipyrromethenelactosylceramid
bodipylacc
molecular
probe
eugen
report
briefli
rins
dmem
bhk
cell
incub
min
mm
bodipylacceralbumin
complex
fbsdmem
allow
intern
traffick
late
endosom
subsequ
extens
rins
cell
incub
hour
fbsdmem
allow
accumul
bodipylacc
golgi
afterward
cell
backexchang
time
fatti
acid
free
albumindmem
analyz
leica
dmr
epifluoresc
microscop
confoc
microscop
adher
bhk
cell
incub
h
tetramethylrhodamin
dextran
mgml
fbsantibiot
absenc
presenc
mm
amiodaron
afterward
extens
rins
cell
chase
plain
medium
control
mm
amiodaron
h
time
suffici
control
cell
transfer
uptaken
dextran
lysosom
end
stain
nuclei
mm
tm
lbpa
evidenc
report
immunofluoresc
cell
analyz
confoc
microscopi
spa
compon
lung
surfact
besid
regul
surfact
turnov
bind
virus
bacteria
present
alveoli
present
alveolar
macrophag
destroy
infecti
agent
spa
lysosom
compar
effect
amiodaron
analogu
degrad
spa
rabbit
alveolar
macrophag
ml
ringer
buffer
mgml
bovin
serum
albumin
uml
penicillin
mg
ml
streptomycin
incub
h
mm
amiodaron
analogu
one
hour
mgml
ispa
continu
presenc
amiodaron
amiodaron
analogu
end
radioact
solubl
cold
trichloroacet
acid
measur
result
express
percent
degrad
control
cell
id
concentr
result
inhibit
calcul
use
data
cell
viabl
trypan
blue
exclus
transferrin
tf
recycl
measur
report
adher
blood
monocyt
rba
cellswel
incub
h
mgml
itf
absenc
presenc
mm
amiodaron
reach
equilibrium
label
cell
rins
icecold
pb
surfac
bound
tf
remov
first
incub
min
mm
deferoxaminemesyl
mm
nacl
mm
cacl
mm
na
acet
ph
incub
min
mm
deferoxaminemesyl
nm
human
apotransferrin
pb
subsequ
cell
rins
icecold
pb
triplic
cultur
incub
min
prewarm
rba
contain
mgml
unlabel
human
tf
mm
amiodaron
end
cell
rins
icecold
pb
lyse
n
naoh
lysat
radioact
measur
use
hyonic
fluor
packard
protein
measur
bradford
method
tf
recycl
express
radioact
lost
cell
respect
time
vero
cell
fb
adher
plate
falcon
milan
itali
densiti
cellswel
incub
h
shiga
toxin
ngml
presenc
mm
amiodaron
min
h
leucin
pb
nci
well
end
cell
wash
time
methanol
fix
min
cold
methanol
wash
time
cold
trichloroacet
acid
tca
final
precipit
dissolv
n
naoh
lysat
use
protein
assay
radioact
count
activ
shiga
toxin
express
decreas
incorpor
h
leucin
acidprecipit
materi
cell
seed
cm
flask
falcon
milan
itali
twentyfour
hour
later
transfect
calcium
phosphat
method
mg
appropri
viral
construct
total
amount
dna
brought
total
mg
ad
empti
vector
stratagen
la
jolla
ca
two
hour
prior
transfect
cell
treat
mm
amiodaron
maintain
till
vlp
harvest
twentyfour
hour
posttransfect
cultur
supernat
collect
cell
lyse
radioimmunoprecipit
assay
ripa
buffer
mm
nacl
mm
na
hpo
mm
nah
po
nonidet
sodium
deoxychol
sodium
dodecyl
sulfat
sd
ph
cultur
supernat
clarifi
low
speed
centrifug
passag
mmpores
filter
releas
vlp
brought
deposit
sucros
cushion
centrifug
rpm
h
beckman
rotor
pellet
vlp
lyse
ripa
buffer
order
examin
intracellular
gag
express
level
viruslik
particl
vlp
releas
cell
vlp
lysat
subject
sdspolyacrylamid
gel
electrophoresi
resolv
protein
electroblot
onto
hybondcextra
membran
amersham
pharmacia
biotech
milan
itali
membran
incub
appropri
antibodi
name
monoclon
antifiv
capsid
antiserum
anti
gag
serotec
dusseldorf
germani
rabbit
anti
capolyclon
antiserum
advanc
biotechnolog
columbia
maryland
usa
follow
appropri
peroxidaseconjug
secondari
antibodi
blot
develop
enhanc
chemiluminesc
reagent
amersham
pharmacia
biotech
milan
itali
exosom
secret
estim
measur
acetylcholinesteras
activ
releas
cell
erytroleukemia
cell
line
human
origin
briefli
cell
incub
h
ml
rpmi
fbsantibiot
mm
amiodaron
end
medium
collect
ice
centrifug
g
min
sediment
cell
g
min
sediment
debri
exosom
sediment
remain
supernat
centrifug
g
h
exosom
pellet
wash
pb
suspend
ml
pb
triton
x
fifti
ml
suspens
incub
min
mm
acetylthiocholin
mm
dithiobi
acid
mm
nacl
mm
kcl
mm
kh
po
mm
na
hpo
mm
cacl
mm
mgcl
ph
final
volum
ml
chang
absorb
follow
continu
correct
spontan
degrad
substrat
enzymat
activ
normal
number
cell
use
express
activ
liber
control
cell
viabil
end
incub
analyz
trypan
blue
exclus
control
amiodaron
treat
cell
data
present
mean
ae
se
pair
test
use
analyz
differ
mean
pair
sampl
singl
factor
anova
use
analyz
differ
sever
group
use
newmankeul
test
data
normal
distribut
dunn
test
data
normal
distribut
level
signific
accept
clinic
experi
indic
patient
treat
amiodaron
display
inclus
bodi
fill
membran
structur
differ
cell
type
accumul
airway
lbpa
poorli
degrad
phospholipid
present
intern
membran
late
endosom
sinc
effect
amiodaron
distribut
lbpa
cell
level
never
studi
bhk
cell
incub
mm
amiodaron
h
distribut
lbpa
analyz
confoc
microscopi
shown
fig
control
cell
lbpa
present
puncta
juxtanuclear
distribut
consist
associ
late
endosom
presenc
amiodaron
lbpaposit
structur
decreas
number
increas
diamet
chang
distribut
juxtanuclear
peripher
fig
quantit
analysi
indic
chang
number
diamet
lbpaposit
structur
concentr
depend
signific
mm
amiodaron
concentr
commonli
found
serum
chronic
treat
patient
fig
mdea
main
metabolit
amiodaron
reach
serum
concentr
close
parent
drug
power
amiodaron
combin
mm
amiodaron
plu
mm
mdea
affect
lbpa
distribut
similarli
mm
amiodaron
fig
b
effect
distribut
lbpa
reproduc
independ
experi
cell
incub
mm
amiodaron
h
number
lbparich
structur
per
cell
profil
decreas
ae
diamet
increas
ae
p
differ
shown
fig
effect
amiodaron
revers
sinc
bhk
cell
incub
h
mm
amiodaron
plain
medium
h
regain
normal
lbpa
distribut
fig
also
show
chang
distribut
lbpa
attenu
inhibit
microtubul
polymer
nocodazol
could
prevent
treatment
ammonium
chlorid
sinc
alkalin
inhibit
accumul
amiodaron
nocodazol
effect
associ
amiodaron
target
cell
conclud
amiodaron
induc
fusion
organel
rich
lbpa
b
process
cytoskeletondepend
revers
c
alkalin
prevent
fusion
inhibit
accumul
amiodaron
within
target
cell
although
amiodaron
increas
ph
acid
organel
lumen
alkalin
role
redistribut
lbpa
f
effect
lbpa
distribut
suggest
amiodaron
interfer
late
compart
endocyt
pathway
sinc
mm
amiodaron
effect
similar
mm
amiodaron
plu
mm
mdea
typic
found
patient
sera
follow
experi
cell
incub
mm
amiodaron
h
time
suffici
develop
amiodaroneinduc
phenotyp
clarifi
structur
basi
interfer
amiodaron
late
endosomeslysosom
analyz
effect
amiodaron
analogu
tabl
end
watersolubl
radioact
measur
id
concentr
analogu
result
inhibit
respect
degrad
control
cell
calcul
spa
calciumdepend
lectin
secret
alveoli
lung
type
cell
besid
regul
lifecycl
lung
surfact
phospholipid
bind
virus
bacteria
mediat
uptak
destruct
alveolar
macrophag
previous
found
amiodaron
inhibit
degrad
spa
lung
cell
vitro
vivo
shown
tabl
effect
degrad
spa
distribut
lbpa
good
extent
concord
sinc
compound
greatest
abil
inhibit
degrad
spa
amiodaron
meami
also
greatest
impact
number
size
lbpaposit
structur
opposit
compound
lowest
activ
spa
degrad
dipam
mopam
weakest
effect
distribut
lbpa
tri
correl
chemicophys
properti
activ
best
result
obtain
arrang
compound
accord
product
pka
watersolubl
ph
fact
shown
tabl
compound
highest
valu
product
meami
amiodaron
strongest
effect
degrad
spa
distribut
lbpa
compound
lowest
valu
dipam
mopam
littl
effect
tabl
also
appear
basic
pka
account
observ
effect
sinc
dipam
rank
toward
top
pka
low
watersolubl
acid
ph
effect
degrad
spa
distribut
lbpa
whole
data
support
view
interfer
endocyt
pathway
depend
abil
accumul
within
acid
organel
agre
recent
evid
indic
accumul
weakli
basic
amin
acid
organel
depend
high
pka
low
propens
ioniz
state
diffus
back
organellar
limit
membran
agreement
interpret
mdea
consid
product
pka
solubl
water
ph
rank
higher
amiodaron
stronger
effect
distribut
lbpa
fig
inhibit
degrad
spa
slightli
lower
id
valu
ae
mm
n
implic
present
data
amiodaron
target
might
locat
might
access
lumen
late
endosom
lysosom
niemannpick
type
c
diseas
accumul
lbpa
facet
gener
disturb
traffic
cell
lipid
specul
might
hold
true
also
cell
treat
amiodaron
explor
possibl
incub
bhk
cell
mm
amiodaron
h
analyz
distribut
unesterifi
cholesterol
glycosphingolipid
sphingomyelin
unesterifi
cholesterol
detect
stain
fix
cell
fluoresc
polyen
antibiot
filipin
shown
fig
control
bhk
cell
unesterifi
cholesterol
associ
small
vesicl
mostli
distribut
around
nucleu
presenc
amiodaron
associ
larger
structur
chang
clearli
discern
presenc
mm
amiodaron
reach
full
express
presenc
mm
amiodaron
give
cell
appear
similar
induc
mm
known
induc
npc
phenotyp
fig
besid
chang
distribut
unesterifi
cholesterol
studi
distribut
sphingomyelin
bhk
cell
expos
mm
amiodaron
fix
incub
first
lysenin
sphingomyelinbind
protein
isol
coelom
fluid
earthworm
eisenia
foetida
antilisenin
antiserum
follow
fluoresc
secondari
antibodi
shown
fig
control
cell
sphingomyelin
associ
plasma
membran
organel
close
plasma
membran
rigor
separ
lbpa
cell
treat
mm
amiodaron
mm
display
intens
stain
respect
control
cell
besid
cell
treat
mm
amiodaron
sphingomyelin
tend
distribut
clump
associ
complex
intern
structur
place
coloc
lbpa
reason
increas
stain
intens
treat
cell
remain
unclear
possibl
amiodaron
render
plasma
membran
sphingomyelin
access
lysenin
distribut
traffick
glycosphingolipid
analyz
incub
bhk
cell
bodipylacc
sphingolipid
analogu
natur
occur
fatti
acid
moieti
replac
n
dimethyl
boron
dipyrromethanedifluorid
acid
cell
allow
intern
bodipylacc
min
allow
load
late
endosom
follow
h
chase
accumul
fluoresc
probe
golgi
analyz
confoc
microscopi
shown
fig
control
cell
bodipylacc
accumul
juxtanuclear
structur
compat
golgi
amiodaron
treat
cell
accumul
round
structur
lack
stain
pattern
typic
golgi
system
fig
also
show
amiodaron
perturb
golgi
organ
sinc
chang
distribut
specif
marker
giantin
furthermor
appear
chang
bodipylacc
distribut
induc
amiodaron
format
larg
cytoplasm
aggreg
differ
distribut
scatter
cytoplasm
dot
observ
presenc
mm
fig
coloc
studi
bodipylacc
specif
golgi
marker
hinder
fact
bodipylacc
exhibit
concentr
depend
shift
fluoresc
emiss
green
red
wavelength
result
excim
format
high
concentr
data
conclud
amiodaron
alter
cell
distribut
sterol
phospholipid
sphingolipid
glycosphingolipid
gener
phenotyp
partial
resembl
niemannpick
type
c
diseas
npc
diseas
accumul
lipid
connect
spatial
function
allevi
phenotyp
obtain
decreas
cholesterol
level
sterolbind
agent
like
methylbcyclodextrin
inhibit
glycosphingolipid
synthesi
increas
lipid
degrad
overexpress
acid
sphingomyelinas
particular
lbpa
accumul
attenu
treatment
methylbcyclodextrin
clarifi
mechan
lipid
accumul
due
amiodaron
bhk
cell
load
h
mm
methylbcyclodextrin
rins
extens
incub
h
plain
medium
mm
amiodaron
mm
process
confoc
microscopi
analysi
lbpa
distribut
result
compar
cell
treat
methylbcyclodextrin
shown
fig
cell
treat
methylbcyclodextrin
amiodaron
similar
effect
decreas
number
increas
diamet
lbpaposit
structur
opposit
pretreat
methylbcyclodextrin
increas
diamet
aggreg
lbpa
induc
amiodaron
worsen
phenotyp
decreas
diamet
increas
number
aggreg
lbpa
induc
allevi
phenotyp
fig
data
conclud
chang
induc
amiodaron
strictli
recapitul
npc
phenotyp
dextran
polysaccharid
good
water
solubl
low
toxic
resist
cleavag
endogen
cell
glycosidas
thu
repres
ideal
tracer
studi
progress
membraneimperm
cargo
along
endocyt
pathway
uptak
dextran
move
endocyt
pathway
end
lysosom
return
extracellular
milieu
wild
type
fibroblast
one
day
may
dispos
uptaken
dextran
studi
effect
amiodaron
traffick
dextran
along
endocyt
pathway
bhk
cell
load
tetramethylrhodamin
dextran
absenc
presenc
mm
amiodaron
chase
h
plain
medium
presenc
mm
amiodaron
time
suffici
control
cell
move
visibl
dextran
lysosom
shown
fig
control
cell
uptaken
dextran
pointlik
distribut
opposit
cell
load
tmrdextran
chase
continu
presenc
amiodaron
retain
greater
fraction
uptaken
dextran
associ
swollen
organel
place
organel
also
contain
lbpa
data
conclud
amiodaron
may
caus
format
vacuol
interf
progress
fluid
phase
endocytosi
furthermor
coloc
lbpa
dextran
swollen
organel
suggest
accumul
watersolubl
materi
may
contribut
also
widen
inclus
bodi
agreement
previou
observ
amiodaron
affect
late
compart
endocyt
pathway
found
abnorm
structur
induc
amiodaron
exhibit
late
endosom
marker
like
marker
earli
endosom
inde
distribut
transient
express
chang
exposur
amiodaron
fig
opposit
shown
fig
control
cell
present
puncta
distribut
around
nucleu
incub
mm
amiodaron
concentr
less
numer
larger
structur
seen
lbpa
aggreg
induc
amiodaron
differ
morpholog
present
clump
tini
ring
fig
spot
arrang
along
rim
dilat
structur
fig
compon
structur
surround
rim
tubulin
fig
interestingli
coloc
lbpa
moder
control
cell
increas
incub
mm
amiodaron
almost
nil
incub
mm
amiodaron
suggest
low
concentr
drug
might
stimul
heterotyp
fusion
organel
high
concentr
could
induc
homotyp
fusion
chang
distribut
induc
amiodaron
agre
chang
distribut
protein
multispan
protein
insert
limit
membran
late
endosomeslysosom
mutat
frequent
caus
niemannpick
type
c
diseas
inde
shown
fig
control
cell
pointlik
distribut
coloc
partial
lbpa
cell
incub
mm
amiodaron
coalesc
larg
aggreg
spatial
separ
lbpa
character
effect
amiodaron
late
endosom
studi
effect
secret
exosom
fig
effect
amiodaron
distribut
tubulin
bhk
cell
incub
h
mm
amiodaron
stain
antibodi
tubulin
analyz
confoc
microscopi
arrow
aggreg
surround
rim
tubulin
bar
mm
vesicl
locat
lumen
late
endosom
multivesicular
bodi
destin
secret
extracellular
milieu
end
cell
incub
without
mm
amiodaron
h
secret
exosom
isol
differenti
centrifug
acetylcholinesteras
activ
associ
measur
found
amiodaron
decreas
secret
acetylcholinesteras
ae
respect
control
cell
n
chang
signific
indic
interfer
exosom
releas
unlik
contribut
significantli
accumul
membran
induc
amiodaron
find
also
indic
amiodaron
perturb
whole
popul
late
endosomeslysosom
amiodaron
effect
transferrin
recycl
shiga
toxin
activ
lentiviru
bud
avail
evid
indic
amiodaron
influenc
distribut
marker
earli
endosom
corrobor
lack
impact
compart
studi
effect
amiodaron
earli
endosomedepend
activ
like
transferrin
recycl
shiga
toxin
traffick
escrtdepend
lentiviru
bud
effect
transferrin
recycl
analyz
load
human
monocyt
label
transferrin
measur
releas
presenc
mm
amiodaron
shown
fig
amiodaron
effect
transferrin
recycl
effect
shiga
toxin
activ
analyz
incub
vero
cell
shiga
toxin
presenc
absenc
mm
amiodaron
time
suffici
toxin
taken
process
earli
endosom
transfer
golgi
move
cytoplasm
inhibit
protein
synthesi
shown
fig
activ
shiga
toxin
decreas
amiodaron
suggest
correct
process
traffick
toxin
human
immunodefici
viru
type
lentivirus
felin
immunodefici
viru
fiv
exit
infect
cell
bud
plasma
membran
process
requir
membran
fission
viral
compon
involv
bud
structur
protein
gag
execut
bud
recruit
host
protein
belong
escrt
complex
understand
whether
amiodaron
interfer
escrt
complex
cell
transfect
construct
express
either
felin
immunodefici
viru
human
immunodefici
type
gagpol
twenti
four
hour
posttransfect
cell
incub
mm
amiodaron
addit
h
viru
like
particl
vlp
releas
supernat
cell
analyz
sdspage
electrophoresi
follow
western
blot
use
antibodi
specif
either
fiv
capsid
protein
shown
fig
amiodaron
affect
synthesi
process
intracellular
gag
protein
inhibit
releas
matur
vlp
suggest
lack
interfer
bud
collect
experi
support
view
amiodaron
affect
late
compart
endocyt
pathway
dronedaron
noniodin
benzofuran
deriv
recent
introduc
clinic
practic
get
around
amiodaron
desir
effect
like
slow
pharmacokinet
iodinerel
thyroid
damag
previou
experi
rabbit
alveolar
macrophag
shown
amiodaron
induc
format
vacuol
inclus
bodi
mechan
format
structur
studi
clarifi
bhk
cell
incub
mm
dronedaron
h
higher
concentr
toxic
cell
distribut
lbpa
unesterifi
cholesterol
analyz
shown
fig
cell
treat
dronedaron
sever
disturb
distribut
lbpa
unesterifi
cholesterol
sinc
dronedaron
rel
high
pka
high
solubl
water
ph
strong
effect
lbpa
distribut
agre
view
physicochem
properti
play
import
role
interfer
late
compart
endocyt
pathway
tabl
sinc
autophagi
upregul
amiodaron
studi
effect
dronedaron
distribut
transient
express
protein
present
step
along
autophag
pathway
found
control
cell
lbpa
pointlik
distribut
wherea
cell
treat
mm
dronedaron
highest
concentr
toler
transfect
cell
mm
amiodaron
lbpa
chang
pointlik
clumplik
distribut
fig
place
aggreg
lbpa
enclos
ringlik
structur
decor
expect
format
amphisom
intermedi
organel
form
autophagi
thu
like
amiodaron
dronedaron
also
alter
distribut
cell
lipid
induc
autophagi
studi
show
vacuol
inclus
bodi
form
presenc
amiodaron
origin
late
compart
endocyt
pathway
sinc
display
marker
normal
associ
late
endosomeslysosom
like
lbpa
also
show
separ
popul
organel
pertain
late
endocyt
compart
affect
indic
lack
coloc
aggreg
lbpa
high
amiodaron
concentr
final
show
amiodaron
affect
whole
late
endosom
activ
sinc
secret
exosom
chang
vacuol
inclus
bodi
appear
form
sever
mechan
block
fluid
phase
endocytosi
inappropri
fusion
organel
collaps
lumen
structur
accumul
undegrad
substrat
accumul
wrongli
traffick
lipid
mechan
could
also
play
exampl
normal
cell
late
endosom
fuse
lysosom
form
hybrid
organel
lysosom
reform
degrad
substrat
complet
posit
decreas
reform
lysosom
hybrid
intermedi
could
contribut
vacuolar
phenotyp
induc
amiodaron
mechan
could
explain
decreas
lysosom
yield
detect
alveolar
macrophag
treat
amiodaron
find
incub
bhk
cell
h
mm
amiodaron
modifi
total
cell
content
protein
insert
limit
membran
lysosom
shown
studi
also
show
amiodaron
directli
affect
earli
endosom
sinc
alter
distribut
earli
endosom
marker
b
inhibit
binari
toxin
requir
function
earli
endosom
activ
like
shiga
toxin
c
disturb
transferrin
recycl
interfer
bud
lentivirus
depend
upon
recruit
highli
conserv
set
protein
dub
endosom
sort
complex
requir
transport
escrt
also
requir
format
multivesicular
bodi
earli
endosom
directli
confirm
lack
interfer
escrt
studi
effect
amiodaron
format
lumen
vesicl
isol
earli
endosom
end
postnuclear
supernat
obtain
bhk
cell
cultur
h
presenc
mm
amiodaron
incub
non
permeant
fluoresc
probe
acid
presenc
energi
donor
system
trap
probe
interior
vesicl
form
inward
bud
endosom
limit
membran
allow
take
place
min
subsequ
quench
extraorganellar
fluoresc
pxylenebispyridinium
bromid
endosom
isol
flotat
fluoresc
associ
measur
separ
experi
found
chang
endosomeassoci
fluoresc
incub
amiodaron
thu
sever
line
evid
indic
amiodaron
direct
effect
earli
endosom
possibl
howev
chronic
exposur
drug
might
reverber
earli
endosom
also
perhap
modifi
global
traffick
membran
sequestr
critic
lipid
cell
chang
induc
amiodaron
thu
far
includ
term
phospholipidosi
term
base
electron
microscopi
describ
format
multilaminar
inclus
vesicl
accumul
lbpa
cholesterol
glycosphyngolipid
cell
expos
amiodaron
compat
accumul
membran
observ
electron
microscop
appear
howev
term
phospholipidosi
fulli
portray
cell
chang
induc
amiodaron
sinc
reflect
accumul
lipid
speci
besid
phospholipid
includ
effect
like
disturb
fluid
phase
endocytosi
data
obtain
amiodaron
analogu
tabl
indic
high
pka
especi
high
watersolubl
acid
ph
import
determin
interfer
amiodaron
late
endosomeslysosom
sinc
basic
pka
low
membran
permeabl
favour
sequestr
weakli
basic
amin
lumen
acid
organel
infer
amiodaron
target
resid
access
lumen
late
endosomeslysosom
natur
amiodaron
target
remain
clarifi
sinc
present
result
compat
inhibit
specif
compon
access
lumin
side
aspecif
effect
like
competit
amiodaron
polycation
lipid
hydrolas
activ
protein
neg
surfac
late
endosom
lysosom
intern
membran
last
mechan
recent
propos
cation
amphiphil
drug
would
explain
accumul
differ
class
undegrad
lipid
membran
traffic
jam
within
late
endosom
lysosom
propens
trap
lumen
acid
organel
could
also
explain
preferenti
effect
amiodaron
late
endosomeslysosom
whose
interior
acid
earli
endosom
side
remain
present
unclear
amiodaron
may
target
specif
set
organel
pertain
late
endosomeslysosom
phenotyp
induc
amiodaron
recal
niemannpick
type
c
diseas
complex
lysosom
storag
disord
character
accumul
differ
sort
lipid
late
endosom
lysosom
defect
lysosom
calcium
homeostasi
uniqu
traffick
defect
npc
diseas
caus
mutat
gene
encod
respect
multispan
transmembran
domain
protein
locat
limit
membran
late
endosomeslysosom
solubl
lysosom
protein
differ
howev
chang
induc
amiodaron
npc
phenotyp
fact
one
side
methylbcyclodextrin
worsen
effect
amiodaron
distribut
lbpa
contrari
allevi
redistribut
lbpa
caus
side
bud
viru
inhibit
npc
cell
treatment
affect
amiodaron
thu
rather
recapitul
whole
pathogenet
cascad
npc
diseas
chang
induc
amiodaron
might
exemplifi
common
theme
observ
damag
late
endosomeslysosom
disturb
pathway
intersect
crucial
spot
exampl
cell
lack
prosaposin
protein
cofactor
necessari
glycosphingolipid
degrad
present
enlarg
electronluc
structur
late
endosom
origin
accumul
unesterifi
cholesterol
display
alter
traffick
bodipylacc
atrial
fibril
predispos
patient
stroke
heart
failur
death
affect
nearli
everi
person
age
year
older
among
convent
antiarrhythm
drug
amiodaron
prove
far
effect
maintain
sinu
rhythm
effect
diminish
long
elimin
halflif
iodineinduc
thyroid
toxic
acut
lung
damag
attempt
reliev
problem
dronedaron
noniodin
benzofuran
deriv
recent
introduc
clinic
practic
dronedaron
multichannel
block
properti
compar
amiodaron
potent
block
peak
sodium
current
acetylcholin
activ
potassium
current
stronger
antiadrenerg
effect
basi
present
evid
appear
molar
basi
dronedaron
least
potent
amiodaron
respect
interfer
late
compart
endocyt
pathway
dronedaron
howev
metabol
rapidli
reach
serum
level
time
lower
patient
treat
amiodaron
thu
clinic
relev
interfer
late
endocyt
compart
remain
determin
interfer
amiodaron
deriv
endocyt
pathway
besid
obviou
clinic
interest
field
cardiolog
might
repres
subject
futur
investig
unrel
area
particular
develop
novel
strategi
infecti
agent
inde
amiodaron
interfer
vitro
life
cycl
sar
coronaviru
mitig
vivo
model
effect
encephalomyocard
viru
shown
valu
treatment
trypanosomacruzi
infect
addit
could
interest
studi
effect
amiodaron
dengu
infect
recent
shown
lbpa
whose
distribut
may
modifi
amiodaron
obligatori
cofactor
entri
dengu
viru
target
cell
amiodaron
induc
format
vacuol
inclus
bodi
interf
late
compart
endocyt
pathway
mechan
format
vacuol
inclus
bodi
includ
disturb
progress
fluid
phase
endocytosi
inappropri
fusion
organel
collaps
lumen
structur
accumul
undegrad
substrat
accumul
wrongli
traffick
lipid
high
watersolubl
acid
ph
crucial
requir
interfer
amiodaron
late
endosomeslysosom
dronedaron
least
potent
amiodaron
respect
interfer
late
compart
endocyt
pathway
interfer
amiodaron
late
endosomeslysosom
may
valu
area
outsid
field
arrhythmolog
